/wp-content/uploads/2026/05/260417-Sanar.png00simon/wp-content/uploads/2026/05/260417-Sanar.pngsimon2026-06-15 15:07:442026-06-17 15:16:15Participated in the Founding Meeting of the Taiwan Regenerative Medicine Business Association
/wp-content/uploads/2026/05/260417-Sanar.png00simon/wp-content/uploads/2026/05/260417-Sanar.pngsimon2026-05-15 15:05:422026-06-17 15:06:11Dr. Ming-Kung Yeh (Former Director of TFDA) Appointed as Board Director
/wp-content/uploads/2026/05/260417-Sanar.png00simon/wp-content/uploads/2026/05/260417-Sanar.pngsimon2026-03-15 15:04:222026-06-17 15:04:46Clinical and Business Development Strategy Presented at Biologics World Taiwan
/wp-content/uploads/2026/05/260417-Sanar.png00simon/wp-content/uploads/2026/05/260417-Sanar.pngsimon2025-11-08 14:49:482026-06-17 14:53:27Latest Research Presented at the 77th Korean Dermatological Association (KDA) International Autumn Meeting
/wp-content/uploads/2026/05/260417-Sanar.png00simon/wp-content/uploads/2026/05/260417-Sanar.pngsimon2025-10-18 14:42:022026-06-17 14:53:51Latest Research Presented at the 30th Annual Meeting of the Japan Society of Clinical Hair Restoration
/wp-content/uploads/2026/05/260417-Sanar.png00simon/wp-content/uploads/2026/05/260417-Sanar.pngsimon2025-09-13 14:39:122026-06-17 14:39:30Latest Research Presented at the 54th Annual European Society for Dermatological Research Meeting (ESDR 2025) in Belgium
Participated in the Founding Meeting of the Taiwan Regenerative Medicine Business Association
Dr. Ming-Kung Yeh (Former Director of TFDA) Appointed as Board Director
Clinical and Business Development Strategy Presented at Biologics World Taiwan
Latest Research Presented at the 77th Korean Dermatological Association (KDA) International Autumn Meeting
Latest Research Presented at the 30th Annual Meeting of the Japan Society of Clinical Hair Restoration
Latest Research Presented at the 54th Annual European Society for Dermatological Research Meeting (ESDR 2025) in Belgium
完成可溶式妝品微針批量生產
透過專利鑑價完成雄性禿技術授權盛鈉生物科技股份有限公司
促進傷口癒合蛋白質藥物BB-101第二期臨床試驗計畫，通過經濟部產業技術司審核，獲得「A+企業創新研發淬鍊計畫-臨床試驗快速審查計畫」補助款3,400萬元
促進傷口癒合蛋白質藥物BB-101取得台灣FDA臨床試驗核准，將於台灣的3個醫學中心開始執行第二期臨床試驗